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The pharmacokinetic profile of a drug can be different when delivered as a nanosuspension 
compared with a true solution, which may in turn affect the therapeutic effect of the drug. 
The goal of this study was to prepare itraconazole nanosuspensions (ITZ-Nanos) stabilized 
by an amphipathic polymer, polyethylene glycol-poly (benzyl aspartic acid ester) (PEG-
PBLA), by the precipitation-homogenization, and study the pharmacokinetic profile of the 
ITZ-Nanos. The particle size and morphology of nanosuspensions were determined by 
Zetasizer and field emission scanning electron microscope (SEM), respectively. The 
dissolution profile was evaluated using a paddle method according to Chinese 
Pharmacopoeia 2015. The level of ITZ in plasma and tissues was measured by a HPLC 
method. The optimized ITZ-Nanos had an average particle size of 268.1 ± 6.5 nm and 
the particles were in a rectangular form. The dissolution profile of ITZ-Nanos was similar 
to that of commercial ITZ injections, with nearly 90% ITZ released in the first 5 min. The 
ITZ-Nanos dis played different pharmacokinetic properties compared with the 
commercial ITZ injections, including a decreased initial drug concentration, increased 
plasma half-life and mean residence time (MRT), and increased concentration in the liver, 
lung, and spleen. The ITZ-Nanos can change the in vivo distribution of ITZ and result in 
passive targeting to the organs with mononuclear phagocyte systems (MPS).
Keywords: itraconazole nanosuspension, process optimization, in vivo pharmacokinetics, tissue distribution, 
passive targeting
INTRODUCTION
Itraconazole (ITZ) is a wide-spectrum triazole antifungal agent that can be  widely used in 
the treatment of both local and systemic fungal infections (Beule and Gestel, 2001; Boogaerts 
and Maertens, 2001). Its antifungal activities are dose-dependent, which means microorganisms 
that are resistant to the drug at a low dose may become susceptible when the dose is increased 
high enough (Rex et  al., 1997). Originally, the drug was formulated and marketed as capsules 
and later developed as a liquid using Hydroxypropyl-β-cyclodextrin (HP-β-CD) as a solubilizer 
to overcome the poor bioavailability of the capsules (Glasmacher and Prentice, 2006). Due to 
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toxicities associated with HP-β-CD (Rabinow et  al., 2007), 
alternative formulations that can deliver a high dose safely 
without HP-β-CD have been explored. Nanosuspensions have 
been used to deliver the poorly soluble ITZ using various 
stabilizers, such as poloxamer 407 (Matteucci et  al., 2006), 
Hydroxypropyl methyl cellulose (HPMC) (Matteucci et  al., 
2007; Matteucci et al., 2009), Polyvinyl alcohol and glycyrrhizinic 
acid (Fernández-Ronco et al., 2015), poloxamer 188 and sodium 
deoxycholate (Rabinow et  al., 2007), tween 80 (Wlaz et  al., 
2015), the hybrid of HPMC and sodium dodecylbenzene 
sulfonate (SDS) (Azad et  al., 2016), and tween 20 (Foglio 
Bonda et al., 2016). As many of these formulations have various 
limitations such as large particle size, poor stability, or toxicity 
for intravenous administration (Decuzzi et  al., 2010; Pu et  al., 
2012), a new stabilizer, polyethylene glycol-poly(Benzyl aspartic 
acid ester) (PEG-PBLA), has been employed to stabilize ITZ 
nanoparticles (Zong et  al., 2017). The PEG-PBLA-stabilized 
ITZ nanosuspensions (ITZ-Nanos) were fabricated by a combination 
of microprecipitation and high-pressure homogenization (mPHPH) 
method (Zong et al., 2017). The ITZ-Nanos demonstrated good 
stability and biocompatibility in comparison with poloxamer 
188-stabilized nanosuspensions. It also showed promising 
antifungal effects.
There has been report that nanoparticles may alter the 
pharmacokinetic profile and tissue distribution of a drug and 
improve its efficacy (Rabinow et  al., 2007; Chiang et  al., 2014; 
Sigfridsson et  al., 2017; Li et  al., 2018). In this work, the 
various factors affecting the preparation of the ITZ-Nanos will 
be evaluated and optimized first, and then their physicochemical 
characteristics were investigated, such as particle size, 
morphology, and in vitro dissolution, followed by evaluation 
of the pharmacokinetic profile and tissue distribution of the 
ITZ-Nanos in comparison to the commercial injections in rats 
and mice. As a result, it was found that ITZ-Nanos can change 
the biodistribution of ITZ and accumulate in MPS organs 
more than ITZ injections. This performance could be  an 
advantage to treat fungus infection in these organs and tissues 
and to reduce the side effect of ITZ to other parts of the 
body (Cao et  al., 2018).
MATERIALS AND METHODS
Materials
PEG-PBLA was synthesized in our own laboratory, and the 
details of the methods can be  found elsewhere (Zong et  al., 
2017). Itraconazole was bought from Zhejiang Huafang 
Pharmaceutical Co., Ltd. (Zhejiang, China). Methanol (HPLC 
grade) was gained by Tianjin Concord Technology Co., Ltd. 
(Tianjin, China). ITZ injections were the product of Xian 
Janssen Pharmaceutical Ltd. (Xian, China). All other reagents 
were analytical grade.
Process Optimization of ITZ-Nanos
ITZ-Nanos were prepared by microprecipitation-homogenization 
method. Firstly, equal amount of ITZ and PEG-PBLA were 
completely dissolved in moderate amount of dimethyl sulfoxide 
(DMSO) at 60°C to form a 50  mg/ml ITZ solution (the good 
solvent phase). In order to obtain a coarse suspension, this 
solution was added to the 50  ml of water (antisolvent phase), 
which was agitated at 1,500  rpm using a magnetic stirrer at 
room temperature. The suspension was continuously stirred 
for 10 min and subsequently homogenized using a NS1001L2K 
high-pressure homogenizer (Niro Soavi S.p.A. Co, Parma, Italy). 
The homogenization process consisted of a preliminary 
homogenization stage of 2 cycles at 200  bar and another 2 
cycles at 500  bar, followed by a main homogenization stage 
at predetermined number of cycles at a pressure of 800, 1,000, 
or 1,200 bar, as indicated in the Results, to obtain the ITZ-Nanos. 
The nanosuspensions were frozen at −20°C for 12  h in a 
refrigerator after 5% (Mannitol, w/v) were added and subsequently 
lyophilized at −50°C for 36  h under vacuum using a freeze 
dryer to obtain a dry powder.
Particle Size and Zeta Potential
ITZ-Nanos were first reconstructed in water for injection to 
gain a liquid dispersion. To observe the physicochemical 
properties of the dispersion, a Malvern Zetasizer Nano ZS90 in 
the light of Dynamic Light Scattering (DLS) were used. Repeats 
of measurement and the average were taken for each sample.
Particle Morphology
A scanning electron microscope (SEM) was used to observe 
the dimension and morphology of particles. Freshly prepared 
samples were sprayed onto SEM specimen holders and coated 
with gold/palladium using a sputter coater after all water was 
removed under ambient conditions. Photomicrographs were 
taken using a JSM-7100F field emission SEM (JEOL Co., Japan) 
with an accelerating voltage of 10  kV.
In vitro Dissolution
The dissolution curve of the ITZ-Nanos in vitro was studied 
using a ZRS-8G dissolution test analyzer by the paddle method 
according to Chinese Pharmacopeia 2015. In a brief, samples 
containing equivalent of 10  mg ITZ were added to 500  ml PBS 
(pH  7.4) containing 0.5% (w/v) SDS at 37°C, and the rotation 
speed of the paddle was set at 75  rpm. At a scheduled time of 
2, 5, 15, 30, 45, 60, and 120 min, 5 ml of the dissolution medium 
was withdrawn and 5  ml of fresh medium was compensated 
immediately to maintain the sink condition following each sampling. 
Samples were filtrated through 0.45 μm filters and analyzed with 
HPLC. All experiments were performed in triplicate.
In vivo Pharmacokinetics of ITZ-Nanos
All animal experiments were approved by the Ethics Committee 
on Animal Experiment of Henan University, and toxic effect 
was not emerged from all the rats. Adult male Sprague Dawley 
rats, weighing about 190–210 g, were fed in rooms at controlled 
temperature and relative humidity for at least 1 week prior to 
pharmacokinetic test. The rats were fasted for 12  h before 
experiments and were randomly and equally divided into two 
groups. ITZ injections or ITZ-Nanos were injected via tail vein 
at a dose of 15  mg/kg. Blood samples (0.5  ml) were collected 
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in heparinized tubes at 0, 0.033, 0.083, 0.25, 0.5, 1, 2, 4, 6, 8, 
and 10  h after administration. After immediate centrifugation, 
plasma samples were stored at −20°C until further analysis.
Tissue Distribution of ITZ-Nanos
Male Kunming species mice weighing 19–21 g were acclimatized 
for at least 1 week prior to experiment, fed with standard diet, 
and permitted water ad libitum. All animal experimentations 
were evaluated and approved by the Ethics Committee on Animal 
Experiment of Henan University, and toxicity did not appear 
in all mice. The mice were randomly divided into two groups. 
ITZ injections and ITZ-Nanos were respectively administered 
intravenously at a dose of 15  mg/kg via the tail vein with a 
1  ml syringe coupled with a 28G1/2 needle. At scheduled time 
(0.25, 2, and 4  h), five mice from each group were anesthetized 
by ethyl ether and sacrificed by cervical dislocation. The liver, 
kidney, heart, lung, and spleen were resected and washed with 
cold saline solution (0.9% NaCl) to remove surface blood and 
then quick dried with tissue paper. An additional incision was 
made in the heart to allow the blood remained in the cardiac 
atria and ventricles squeezed out. After collection, tissue samples 
were stored at −20°C until further analysis.
High-Performance Liquid  
Chromatography
ITZ concentrations in dissolution medium were determined 
using a Waters 2695 HPLC system (Waters Corporation, Milford, 
USA) equipped with an automatic sampler and a variable 
wavelength UV detector set at 263 nm. A RP-C18 chromatographic 
column (5  mm, 250  ×  4.6  mm, Thermo Syncronis, Waltham, 
USA) was utilized with the column temperature at 25°C. The 
mobile phase composed of methanol and water (85:15, v/v), 
and the flow rate was 1.0 ml/min. A 20 μl sample was injected 
into the column for analysis.
For the analysis of plasma samples, nimodipine (2.5  μg/ml) 
was used as an internal standard. About 100  μl of methanol 
and 200 μl of the internal standard solution were added to 100 μl 
of plasma, and the mixture was vortexed for 3 min. The samples 
were subsequently subjected to ultrasonication for 30  s and 
centrifuged at 13,000  g for 10  min. The supernatants were taken 
and dried under nitrogen atmosphere. The residuum was reproduced 
with 100  μl of methanol and injected into a HPLC column for 
analysis as described above. Tissue samples were weighed accurately 
and homogenized by a DY89-1 tissue homogenizer (Ningbo 
Scientz Biotechnology Co., Ltd. China) after the addition of 300 μl 
physiologic saline, which contains 10% (v/v) methanol. These 
samples were subsequently processed the same way as serum 
samples and analyzed by HPLC as mentioned above.
Data Analysis
Statistical analysis was performed using two-tailed Student 
t-test. In vivo pharmacokinetic parameters were calculated 
with a DAS 2.0 pharmacokinetic program (Mathematical 
Pharmacology Professional Committee of China, Shanghai, 
China). Area under curve (AUC) in the tissue distribution 
test was calculated using the linear trapezoidal method, and 
the Cmax values were observed from the curves in the tissue 
distribution experiment. To estimate the targeting efficiency 
of ITZ-Nanos, relative uptake rate (Re) and ratio of peak 
concentration (Ce) were calculated by the following equations.
  R X N X Ie AUC AUC= ( ) ( )/  (1)
  C C C
N Ie
= ( ) ( )max max/  (2)
where AUCX is behalf of the area under time-concentration 
profile of No. X organ or tissue. The N and I represent 
ITZ-Nanos and ITZ injection, respectively.
RESULTS AND DISCUSSION
Process Optimization for the Preparation 
of ITZ-Nanos
In this work, a microprecipitation-high-pressure homogenization 
process was used to obtain ITZ-Nanos. In order to find the 
optimum conditions for this process, the influences of drug 
concentration, homogenization pressure, and number of cycles 
on the particle dimension of the nanosuspensions were evaluated. 
While the other process parameters were fixed, the effect of 
drug concentration was evaluated in the range from 1 to 3  mg/
ml as shown in Figure 1A. It can be  seen that the particle size 
increased slightly when the concentration increased from 1 to 
2  mg/ml and then decreased with a further increase of drug 
concentration to 3 mg/ml. The PDI remained virtually unchanged 
when the concentration increased from 1 to 2 mg/ml, but increased 
dramatically when the concentration increased from 2 to 3  mg/
ml. Although the particle size was smallest at the 3  mg/ml, the 
PDI was largest, which was an indication that the physical stability 
was likely to be  poor (Verma et  al., 2011; Papdiwal and Pande, 
2014; Ren et  al., 2016; Guo et  al., 2017). Therefore, 2  mg/ml 
was considered to be  the ideal concentration as the particle sizes 
and PDIs were not considerably higher that of 1  mg/ml. It can 
be  seen from Figure 1B that an increase of the homogenization 
pressure from 800  bar to 1,000  bar reduced the particle sizes 
and PDI substantially, but a further increase to 1,200  bar failed 
to reduce these any further. As the number of homogenization 
cycles increased, the particle size and PDI decreased first and 
then increased lightly, with the smallest particle size observed 
at 25 homogenization cycles (Figure 1C). Therefore, the conditions 
adopted were 2  mg/ml drug concentration, 1,000  bar pressure, 
and 25  cycles through the homogenizer.
Particle Size, Zeta Potential, and 
Morphology
As seen from Table 1, the average particle size, polydispersity 
index, and zeta potential did not change significantly after 
lyophilization. The lyophilized ITZ-Nanos presented a rectangular 
shape (Figure 2), different from the claviform exhibited by 
the bulk drugs, which is the same as those reported by Wong 
(Wong et  al., 2006). However, the particle size of ITZ-Nanos 
was several times smaller compared with the bulk drugs 
(1–5  μm). The dimension of ITZ-Nanos measured by SEM 
(Figure 2) was conformed to that by DLS. It means that 
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dimension of ITZ-Nanos in this research was close to ITZ 
nanosuspensions by Wong et  al. (2006) but was far smaller 
than those by Rabinow et  al. (2007). This implied that ITZ 
in the ITZ-Nanos could dissolve more quickly in blood and 
reduce its distribution in organs of the MPS, and consequently, 
the depot effect in MPS might not be  as evident as those by 
Rabinow et  al. (2007). Such potential effect can be  ascribed 
to the effect of dimension and appearance on the in vivo 
performance of nanoparticles (Decuzzi et  al., 2010).
In vitro Dissolution
The dissolution rate of ITZ-Nanos, in comparison with ITZ 
injections, was investigated, and the results were shown in 
Figure 3. The dissolution profile of ITZ from nanoparticles was 
essentially similar to that of the injections, with the accumulative 
A
B
C
FIGURE 2 | SEM images of (A) crude ITZ, (B) ITZ-Nanos before lyophilizing, 
and (C) ITZ-Nanos after lyophilizing.
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FIGURE 1 | Influence of the drug concentration (A), homogenization pressure 
(B), and homogenization cycles (C) on the particle size reduction of ITZ-Nanos.
TABLE 1 | The mean particle sizes and zeta potentials of ITZ-Nanos.
Parameters Before lyophilization After lyophilization
Size (nm) 268.1 ± 6.5 289.5 ± 6.4
PDI 0.157 ± 0.019 0.187 ± 0.017
Zeta potential (mV) −17.5 ± 0.8 −19.3 ± 1.8
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dissolution rate of ITZ-Nanos being reached 86.0% within 2 min 
and ITZ injections being 91.0% within 2  min. The reasons for 
the fast dissolution of the ITZ-Nanos were considered to be mainly 
owing to the small dimension of the nanoparticles. Slow dissolution 
rate is one of the key issues affecting the clinical application of 
newly developed medicines that are poorly soluble in water, and 
reducing particle size has been one of the often adopted strategies 
to conquer the problem. The micronization of poorly soluble 
drugs, where particles are reduced to the micrometer range, 
FIGURE 3 | In vitro dissolution of ITZ injection and ITZ-Nanos.
FIGURE 4 | Mean plasma concentration-time curves of five rats after I.V. administration of ITZ-Nanos and ITZ injection at 15 mg/kg.
TABLE 2 | Comparison of the main PK parameters for two formations.
Parameter ITZ injection ITZ-Nanos
AUC0–∞ (mg/l × h) 10.01 ± 1.76 8.76 ± 1.42
MRT0–∞ (h) 2.67 ± 0.22 2.92 ± 0.39
V/(l/kg) 4.43 ± 0.48 5.13 ± 0.70
CL (l/h/kg) 1.50 ± 0.14 1.54 ± 0.09
t1/2zeta (h)* 1.55 ± 0.08 2.31 ± 0.25
*Statistical significance (p < 0.01).
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improves dissolution rate because of the associated increase of 
surface area without actually increasing the solubility of the drug 
(Teeranachaideekul et  al., 2008; Chavhan, 2013). However, when 
the particle size is decreased to the nanometer range, through 
formulation technologies, such as nanoemulsion (Bu et  al., 2014; 
Yadav et  al., 2016; Kaur et  al., 2017), liposome (Koshkina et  al., 
2004), solid lipid nanoparticle (Baek and Cho, 2015), micelle 
(He et  al., 2016; Chen et  al., 2017), and nanosuspension (Ghosh 
et al., 2008; Maged et al., 2016; Yin et al., 2016), both the surface 
area and the solubility of the drugs are increased significantly, 
resulting in substantially increased dissolution rate. The particle 
sizes of the ITZ-Nanos were below 300  nm; therefore, both the 
total surface area and the solubility of the ITZ-Nanos would 
have been increased. Although the dissolution profiles of the 
ITZ-Nanos were similar to ITZ injections, its toxicity could 
be  extremely reduced on account of the better biocompatibility 
of the stabilizer used in the nanosuspensions than that of 
cyclodextrin in the ITZ injections (Zong et  al., 2017).
In vivo Pharmacokinetics of ITZ-Nanos
The blood concentration-time profiles of ITZ after I.V. administration 
are shown in Figure 4, and the relevant pharmacokinetic parameters 
obtained are listed in Table 2. The results indicated that ITZ-Nanos 
exhibited a slightly delayed clearance in the blood compared to 
ITZ injections. In addition, the MRT (2.92  ±  0.39  h) and the 
half-life (t1/2, 2.31  ±  0.25  h) of the ITZ-Nanos were longer than 
those observed of the ITZ injections (2.67 ± 0.22 h, 1.55 ± 0.08 h). 
This could be  due to that ITZ-Nanos were partly recognized and 
captured by reticuloendothelial system (RES) and subsequently 
released back into the systemic circulation gradually (Peters et al., 
2000; Pu et  al., 2012). As reported in literatures, phagocytosis of 
nanoparticles by RES organs following I.V. injection may take 
from several minutes to hours, depending on the dimension and 
ingredient of the particle (Manjunath and Venkateswarlu, 2006). 
The ITZ-Nanos phagocytosed by RES might dissolve slowly in 
phagocytes and release slowly into blood circulation and maintain 
a blood level longer than ITZ injections. This way, the captured 
TABLE 3 | The AUC(0–t) and Cmax in different tissues of mice (n = 5).
Tissues AUC(0–t) (ng·h/mg)   Re   Cmax (ng/mg)   Ce
ITZ injection ITZ-Nanos ITZ injection ITZ-Nanos
Heart 11.92 ± 1.09 5.82 ± 0.49 0.49 5.45 ± 0.49 1.95 ± 0.21 0.36
Liver 30.58 ± 3.16 39.06 ± 4.12 1.28 21.04 ± 2.08 24.97 ± 2.38 1.19
Spleen 2.06 ± 0.18 12.61 ± 1.31 5.78 1.05 ± 0.12 5.34 ± 0.53 3.75
Lung 5.06 ± 0.49 9.44 ± 0.96 1.87 6.19 ± 0.57 7.15 ± 0.67 1.16
Kidney 7.49 ± 0.76 4.35 ± 0.45 0.58 6.15 ± 0.55 2.90 ± 0.32 0.47
FIGURE 5 | Tissues distribution of ITZ after I.V. administration of two formulations in mice (n = 5) at 0.25 h, 2 h, and 4 h.
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ITZ-Nanos by RES can serve as a drug depot slowly releasing 
drug into the systemic circulation to prolong drug action. This 
could be  beneficial to certain drug classes, whose efficacy are 
enhanced by a prolonged therapeutic time and peak plasma 
concentration, such as the case of itraconazole. But the depot 
effect in this study was not as substantial as that reported in 
another study (Rabinow et  al., 2007), probably due to the small 
particle size and fast dissolution of ITZ-Nanos.
Tissue Distribution of ITZ-Nanos
Figure 5 shows the mean drug concentration with time in tissues 
after I.V. administration of the ITZ formulation to mice. The 
AUC(0–4), Cmax, the Re, and Ce of the two formulations in the 
various tissues are shown in Table 3. It can be seen from Table 3 
that the concentrations of ITZ in liver, lung, and spleen were 
remarkably higher for ITZ-Nanos compared to those of ITZ 
injections, and the Re and Ce values in the three tissues were 
larger than those in other tissues, suggesting ITZ-Nanos passively 
targeted to these organs. This could be  due to that ITZ-Nanos 
were recognized as foreign substances and quickly endocytosed 
by phagocytes of the mononuclear phagocyte system (MPS) in 
blood circulation (Pu et al., 2012). The results of tissue distribution 
of ITZ further confirmed that RES-related organs, containing 
liver, lung, and spleen, could potentially serve as a drug reservoir 
depot for prolonged effect. Similar consequences were also 
discovered by others for clofazimine, 10-HCPT, and curcumin 
nanosuspensions (Peters et  al., 2000; Pu et  al., 2012; Bi et  al., 
2017). Another noticeable result from Figure 5 and Table 3 is 
that the ITZ concentration in the kidney is lower for ITZ-Nanos 
compared with ITZ injections, which is a potential advantage 
of ITZ-Nanos in reducing the toxicity of the drug to kidney.
CONCLUSIONS
The effects of drug concentration, homogenization pressure, 
and number of cycles of homogenization were evaluated, 
and the optimal conditions were 2  mg/ml, 1,000  bar, and 
25 times, respectively. The dimension of ITZ-Nanos did not 
alter considerably after lyophilization, and the ITZ in the 
nanosuspensions displayed a rectangular shape. The ITZ-Nanos 
had a similar dissolution profile to that of ITZ injection 
with about 90% of the drug released in the first 5  min. The 
results indicated that ITZ-Nanos could moderately prolong 
circulating time in plasma and increase exposure time in 
rats. It was found that ITZ-Nanos accumulated in MPS 
organs, such as liver, spleen, and lung, more than ITZ 
injections. This performance could be  an advantage to treat 
fungus infection in these organs and tissues and to reduce 
the side effect of ITZ to other parts of the body. It remains 
future work to evaluate the implications of such changes on 
the antifungal activity in vivo.
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